Biotop-report 2011

18

B i o T O P i c s   4 2 _

B i o T O P   R e p o r t   2 0 1 1

Evestra GmbH

Evestra GmbH, founded in July 2008, is 

a fully owned subsidiary of Evestra Inc. 

located  in  San  Antonio  Texas.  Evestra 

GmbH serves as the development and 

commercialization center for Europe and 

ROW. Evestra’s mission is to develop and 

commercialize steroid-based female 

healthcare products. 

The  development  strategy  of  the  com-

pany includes product ideas with known 

compounds as well as New Chemical 

Entities. 

Evestra is conducting research and 

product development in a number of 

in-demand, but as yet unmet, medi-

cal need areas of women’s health such 

as hormonal-dependent breast cancer 

and endometriosis. The company is also 

pursuing  different  projects  in  fertility 

control, e. g. a new estrogen for oral 

contraception, with superior pharmaco-

logical properties compared to the stan-

dard drug ethinyl estradiol. 

Several patents on new composition of 

matter, new technical processes and 

use patents have been filed during the 

last three years and support the strong 

intellectually property position.

Evestra is concentrating on R&D and will 

seek more partners for commercializa-

tion. More detailed information can be 

found on our web side.

Address

Evestra GmbH

Britzer Strasse 26

12439 Berlin · Germany

EU Contact

Prof. Klaus Nickisch · Managing Director 

Phone [phone]

[e-mail]

www.evestra.com

LGC Genomics

LGC is an international science-based 

company and market leader in analytic-

cal, forensic and diagnostic services and 

reference standards. LGC Genomics is the 

division of LGC with specific expertise in 

high quality, cutting-edge genomic and 

related services and products. We offer a 

broad portfolio to a wide range of clients 

including pharmaceutical and biotech-

nology companies, private and pub-

lic research organisations and medical 

institutions.  Our  quality  management 

system is certified by ISO 9001:2008.

Address

LGC Genomics GmbH

Ostendstrasse 25 • TGS Haus 8

12459 Berlin • Germany

Phone [phone]

[e-mail]

www.lgcgenomics.com

1. DNA sequencing services

 

p

Single read sequencing

 

p

Primer walking projects

 

p

MTP sequencing (96/384 well)

2. Genomic services

 

p

Next generation sequencing 

(Roche/454 and Illumina HiSeq 2000)

 

p

Re-sequencing of genes and/or 

genomic regions

 

p

Library services

 

p

Cloning and sequencing

 

p

Identification of microorganisms

 

p

Genotyping services

 

p

Pharmacogenetic services

 

p

Bioinformatics services

3. Nucleic acid preparation

3.1. Automated DNA extraction

 

p

Kits based on magnetic micro 

particles

 

p

Application of kits on different 

automated systems

 

p

Magnetic particle manipulators

3.2. Nucleic acid extraction service

 

p

DNA, RNA (manual & automated)

Advancing genomic services 

and products

Tel: [phone] 

Email: [e-mail]  

www.lgcgenomics.com

© LGC Limited, 201

1. 

All rights reserved.

---

19

B i o T O P i c s   4 2 _

B i o T O P   R e p o r t   2 0 1 1

GILUPI GmbH

The 

GILUPI GmbH, founded in March 

2006, develops, markets and sells 

innovative and new medical devices 

to detect and isolate rare blood cells, 

with a strong focus on the prenatal and 

cancer  diagnostic  market.  The  existing 

methods  in  the  field  of  prenatal  diag-

nostics bear the risk of miscarriage. The 

associated risk is about 1%.

 

Cancer diseases are detected relatively 

late. Biopsy procedures can therefore be 

applied only in late stages of the disease. 

Currently there are no simple therapy 

accompanying examinations available.

The  GILUPI  product  offers  a  minimally 

invasive  application  and  a  specific 

enrichment of certain cells from the 

blood stream. A subsequent diagnosis, 

in prenatal detection for example, 

allows the proof of chromosomal aber-

rations (e. 

g. trisomy). Compared to 

today’s procedure, the detector can be 

used as early as in pregnancy week 10. 

In case of cancer diagnosis, a difference 

has to be made between the early diag-

nosis of a tumor and the monitoring of 

a cancer therapy. The GILUPI product will 

give access to higher numbers of Cir-

culating  Tumor  Cells  (CTC)  compared  to 

existing methods, by a percentage of 

over  80.  The  CTC  can  then  be  analyzed 

with existing tumor biopsy methods, 

allowing an early personalized and 

optimized therapy.

Address

GILUPI GmbH

Am Mühlenberg 11

14476 Potsdam OT Golm · Germany

Contact

Klaus Lücke

Phone [phone]

Fax 

[phone]

[e-mail]

www.gilupi.com

BIOTECON Diagnostics GmbH

BIOTECON  Diagnostics  was  founded  in 

1998 and currently has 50 employees. 

The  company  provides  superior  experi-

ence in microbiological service testing 

of food, pharmaceutical and cosmetics 

products. 

The  company’s  focus  is  the  develop-

ment of rapid and innovative detection 

systems for pathogenic, spoilage and 

genetically  modified  organisms  (GMO) 

based on real-time PCR. The 

foodproof

®

 

product line includes detection kits as 

well as sample preparation kits for the 

extraction and purification of DNA from 

multiple food matrices. 

As an international biotechnology com-

pany,  BIOTECON  Diagnostics  has  been 

developing, producing and marketing 

these products through a continually 

growing network of local distributors 

and worldwide sales channel partners. 

Additionally the company offers the 

new 

foodproof

®

  RoboPrep+  Series  as 

the  first  commercially  available  system 

for automated food sample preparation 

and subsequent PCR setup. It has been 

developed as a cost-effective tool for 

food pathogen testing, reducing hands-

on time and increasing lab efficiency.

Due to close contacts to many compa-

nies  in  the  industry,  BIOTECON  Diagnos-

tics is well aware of customers’ current 

and  future  challenges.  The  company 

is  able  to  provide  flexible  solutions  to 

production and processing companies 

through new and economical approach-

es.  Furthermore,  BIOTECON  Diagnostics 

also offers contract development and 

production to other biotech companies.

For safer food: BIOTECON Diagnostics – 

simply builds up trust.

Address

BIOTECON Diagnostics GmbH

Hermannswerder 17

14473 Potsdam · Germany

Contact

Kornelia Berghof-Jäger, Ph. D. 

Chief Executive Officer

Alois Schneiderbauer 

Chief Business Officer

Phone [phone]

Fax 

[phone]

[e-mail]

---